Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.

Two studies were carried out (A and B) in order to assess the effectiveness of ifosfamide administered with mesna (IFO/M) in the treatment of small cell lung cancer. The first study (A) was a cross-over study; the second (B) was a randomized trial, and in B IFO/M was evaluated earlier in the course of the disease. IFO/M given be infusion is effective as second-line therapy and can be administered with other cytotoxics at the doses reported here earlier in the course of the disease. The complete remission rates were high.